NO20071113L - Anvendelse av Alk 5-inhibitorer for a modulere eller inhibere myostatinaktivitet og oppna okt mengde magert vev hos dyr - Google Patents

Anvendelse av Alk 5-inhibitorer for a modulere eller inhibere myostatinaktivitet og oppna okt mengde magert vev hos dyr

Info

Publication number
NO20071113L
NO20071113L NO20071113A NO20071113A NO20071113L NO 20071113 L NO20071113 L NO 20071113L NO 20071113 A NO20071113 A NO 20071113A NO 20071113 A NO20071113 A NO 20071113A NO 20071113 L NO20071113 L NO 20071113L
Authority
NO
Norway
Prior art keywords
animals
amount
alk
modulate
inhibitors
Prior art date
Application number
NO20071113A
Other languages
English (en)
Inventor
David G Sawutz
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of NO20071113L publication Critical patent/NO20071113L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

Oppfinnelsen angår en fremgangsmåte for å øke mengden muskelvev hos dyr. I ett aspekt innbefatter fremgangsmåten å administrere en effektiv mengde av en ALK5-reseptorinhibitor (formel I) til et dyr i tilsttekkehg tid til å oppnå den ønskede virkning.
NO20071113A 2004-07-29 2007-02-27 Anvendelse av Alk 5-inhibitorer for a modulere eller inhibere myostatinaktivitet og oppna okt mengde magert vev hos dyr NO20071113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59235904P 2004-07-29 2004-07-29
PCT/US2005/026607 WO2006025988A1 (en) 2004-07-29 2005-07-27 Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals

Publications (1)

Publication Number Publication Date
NO20071113L true NO20071113L (no) 2007-02-27

Family

ID=35595039

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071113A NO20071113L (no) 2004-07-29 2007-02-27 Anvendelse av Alk 5-inhibitorer for a modulere eller inhibere myostatinaktivitet og oppna okt mengde magert vev hos dyr

Country Status (14)

Country Link
US (1) US20060194845A1 (no)
EP (1) EP1771171A1 (no)
JP (1) JP2008506787A (no)
CN (1) CN101031294A (no)
AR (1) AR050187A1 (no)
AU (1) AU2005280496B2 (no)
BR (1) BRPI0513914A (no)
CA (1) CA2576734C (no)
MX (1) MX2007001118A (no)
NO (1) NO20071113L (no)
PE (1) PE20060729A1 (no)
TW (1) TW200616621A (no)
WO (1) WO2006025988A1 (no)
ZA (1) ZA200700681B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
WO2008136739A1 (en) * 2007-05-04 2008-11-13 Jana Pickova Compound feed for aquaculture
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CN101684457B (zh) * 2009-07-27 2013-01-09 中国科学院广州生物医药与健康研究院 I型转化生长因子受体抑制剂在产生诱导多能干细胞中的应用及其方法
EP2694653A2 (en) * 2011-04-05 2014-02-12 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Compounds and methods for altering activin receptor-like kinase signalling
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
PT2880053T (pt) 2012-08-01 2020-05-22 Ikaika Therapeutics Llc Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4
US10265372B2 (en) 2014-08-12 2019-04-23 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2022511112A (ja) 2018-12-11 2022-01-28 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
US20220143136A1 (en) 2018-12-21 2022-05-12 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP2023502662A (ja) 2019-11-22 2023-01-25 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
US20230414711A1 (en) * 2020-11-13 2023-12-28 The Jackson Laboratory Therapeutics targeting transforming growth factor beta family signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
CN100567322C (zh) * 1999-01-21 2009-12-09 梅塔莫菲克斯公司 抑制生长分化因子活性的多肽及表达该多肽的细胞
ATE231143T1 (de) * 1999-04-09 2003-02-15 Smithkline Beecham Corp Triarylimidazole
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
JP2008506787A (ja) 2008-03-06
MX2007001118A (es) 2007-03-15
EP1771171A1 (en) 2007-04-11
TW200616621A (en) 2006-06-01
WO2006025988A1 (en) 2006-03-09
BRPI0513914A (pt) 2008-05-20
US20060194845A1 (en) 2006-08-31
CN101031294A (zh) 2007-09-05
AU2005280496B2 (en) 2009-10-08
AR050187A1 (es) 2006-10-04
ZA200700681B (en) 2008-07-30
CA2576734A1 (en) 2006-03-09
AU2005280496A1 (en) 2006-03-09
CA2576734C (en) 2010-03-16
PE20060729A1 (es) 2006-08-12

Similar Documents

Publication Publication Date Title
NO20071113L (no) Anvendelse av Alk 5-inhibitorer for a modulere eller inhibere myostatinaktivitet og oppna okt mengde magert vev hos dyr
ATE550031T1 (de) Zusammensetzungen und verfahren für die lipomodellierung
NO20052894L (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20065544L (no) Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander.
NO20064362L (no) Forbindelser, farmaseutiske sammensetninger og fremgangsmater for anvendelse i behandling av metabolske sykdommer
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
NO20063191L (no) Aminobenzazoler som P2Y1-reseptorinhibitorer
PL402389A1 (pl) Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat
ATE318267T1 (de) Einige alkylendiamin-substituierte heterocyclen
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CY1110498T1 (el) Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα
EA200700058A1 (ru) Соединения, композиции и способы их использования
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA200400154A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
YU81991A (sh) Sinergističke terapeutske kompozicije i postupci
UY27992A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht
NO20083836L (no) N-hydroksyakrylamidforbindelser
PT1185649E (pt) Promotor do gene da miostatina e inibicao da sua activacao
NO20063652L (no) Modulering av peroksiomproliferasjons-aktiverte reseptorer
CY1105796T1 (el) Θepαπεια οξεωσης της μεγαλης κοιλιας των μηρυκαστικων με αναστολεις αλφα-αμυλασης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application